The trolls that peppered these threads with vitriol and ignorant and false scaremongering on tumorigenicity, trial failures, balance sheet shortcomings, cash-burn, etc, etc, for years, now want to have (half) decent discussion - apparently we are in the trenches together now.
Any CYP holders/investors who read MSB threads - and should, the better posters at least, for information pertinent to CYP - will be familiar with how little the MSB posters we have trying to denigrate CYP on these threads, contribute to constructive discussion that side of the MSC fence too.
Silviu got far too greedy on his Remestemcel-L pricing and flew the equity markets too close to the sun for their comfort. That has inevitably rubbed off on CYP's short-term share pricing too. But it really just ups the total addressable market value for CYP in its future ambitions. (again, I hold both MSB and CYP, to my chagrin, for disclosure)
CYP Price at posting:
16.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)